- Home
- ENOV vs CNTA Comparison
ENOV vs CNTA Comparison
Compare ENOV & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENOV
- CNTA
- Stock Information
- Founded
- ENOV 1995
- CNTA 2020
- Country
- ENOV United States
- CNTA United Kingdom
- Employees
- ENOV N/A
- CNTA N/A
- Industry
- ENOV Fluid Controls
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ENOV Industrials
- CNTA Health Care
- Exchange
- ENOV Nasdaq
- CNTA Nasdaq
- Market Cap
- ENOV 1.7B
- CNTA 1.6B
- IPO Year
- ENOV 2008
- CNTA 2021
- Fundamental
- Price
- ENOV $33.65
- CNTA $14.07
- Analyst Decision
- ENOV Strong Buy
- CNTA Strong Buy
- Analyst Count
- ENOV 5
- CNTA 10
- Target Price
- ENOV $58.00
- CNTA $28.78
- AVG Volume (30 Days)
- ENOV 1.6M
- CNTA 1.2M
- Earning Date
- ENOV 08-06-2025
- CNTA 08-12-2025
- Dividend Yield
- ENOV N/A
- CNTA N/A
- EPS Growth
- ENOV N/A
- CNTA N/A
- EPS
- ENOV N/A
- CNTA N/A
- Revenue
- ENOV $2,150,191,000.00
- CNTA $15,000,000.00
- Revenue This Year
- ENOV $8.23
- CNTA N/A
- Revenue Next Year
- ENOV $6.18
- CNTA N/A
- P/E Ratio
- ENOV N/A
- CNTA N/A
- Revenue Growth
- ENOV 18.32
- CNTA 118.88
- 52 Week Low
- ENOV $28.83
- CNTA $8.46
- 52 Week High
- ENOV $49.83
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- ENOV 56.27
- CNTA 60.47
- Support Level
- ENOV $30.84
- CNTA $12.74
- Resistance Level
- ENOV $33.95
- CNTA $14.27
- Average True Range (ATR)
- ENOV 1.15
- CNTA 0.66
- MACD
- ENOV 0.33
- CNTA 0.12
- Stochastic Oscillator
- ENOV 90.53
- CNTA 85.57
About ENOV Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.